

News Release June 13, 2017

## **CEN TOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine**

- *International consortium of investors led by TVM Capital Life Science together with DPE Deutsche Private Equity, Careventures and CIC Capital*
- *CEN TOGENE will continuously expand its R&D activities, including biomarkers and companion diagnostic solutions, as well as broadening its global genetic diagnostics activities for early, precise diagnosis and treatment of rare diseases*

Rostock/Berlin, 13.06.2017 – CEN TOGENE AG, a worldwide leader in the field of genetic diagnostics for rare diseases, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deutsche Private Equity, Careventures and CIC Capital. The proceeds of the financing will be used to accelerate the company's further growth and expansion plans in the business segments of worldwide Genetic Testing, Pharmaceutical Collaborations and Big Data-Solutions. CEN TOGENE AG already commands the largest test portfolio for rare genetic diagnostics in the world having analyzed patients from over 110 countries, allowing CEN TOGENE to generate unique and global insights into the epidemiological basis of hereditary disorders and the link between genotypic and phenotypic data. "There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases. This creates a tremendous market opportunity for us", comments Prof. Arndt Rolfs, MD, CEO and Founder of CEN TOGENE AG. "We are very pleased to have this international investor consortium on board who not only shares our vision for future growth to put innovation into precision medicine, but also provides the necessary access to an international network to realize our vision on a real global basis."

CEN TOGENE aims to increase its presence in the U.S. and China and intends to expand its current presence in other regions, mainly in the MENA region and Latin America. Additionally, the funding will enable the company to broaden its portfolio of biomarkers, companion diagnostics and tools for oncogenetics.

"We are very glad to support a highly innovative company, already a world leader in its field, on its journey towards innovating modern medicine, genetic diagnostics and the treatment of genetic diseases", adds Dr. Hubert Birner, Managing Partner, TVM Capital Life Science. "CEN TOGENE, headquartered in Rostock, is the second investment in the history of TVM Capital Life Science residing in the federal state of Mecklenburg-Western Pomerania. That proves that Germany's vibrant life sciences and biotech industry is widespread across the country."

“CENTOGENE’s genetics database coupled with its in-depth clinical knowledge positions the company perfectly to continue on its growth trajectory. It uniquely addresses the challenges of the pharmaceutical industry in a market that develops towards evidence-based and personalized medicine”, notes Guido Prehn, Partner at DPE Deutsche Private Equity.

"We are proud to support one of the world leaders in genetic testing and biomarkers discovery. With an exceptional scientific and development team, we are confident that CENTOGENE will strengthen its presence over the five continents", says Eric Souetre, Managing Partner of Careventures.

“We are very happy that the investment in CENTOGENE, a company with strong fundamentals, is the first implementation of our new international strategy in Germany aiming at investing in growing midsize companies alongside renowned investors”, comments Sébastien Neiss, Director in charge of Germany for CIC Capital.

Dr. Hubert Birner, TVM Capital Life Science, Eric Souetre, Careventures and Guido Prehn, DPE Deutsche Private Equity, will join the Supervisory Board of the company.

*+++ ends +++*

#### **About CENTOGENE**

Founded in 2005, CENTOGENE AG is the worldwide leader in the field of genetic diagnostics for rare diseases. Led by Prof. Arndt Rolfs, MD, CEO and Founder, CENTOGENE AG provides test portfolios of over 3,100 single genes, including 200 panels, whole exome and whole genome testing. The company is currently receiving samples from over 110 countries, with approximately 120,000 analyzed individuals in their proprietary database - CentoMD®, the largest, fully curated, mutation database for rare diseases. CENTOGENE AG has been growing at a CAGR of over 40% over the past five years, with approximately 300 employees as of 31 May 2017.

More information: [www.centogene.com](http://www.centogene.com)

#### **Media Contact:**

Doreen Niemann, CEO Office, [CEO-Office@centogene.com](mailto:CEO-Office@centogene.com)

+49 381 203652 181

#### **About TVM Capital Life Science**

TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and more than US\$1.4bn raised and under management. The TVM Capital Life Science international team looks back on more than 130 investments and over 90 exits, including more than 45 initial public offerings on all major U.S. and European stock exchanges and has gained unrivalled international investment experience with a long track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets.

More information: [www.tvmlifescience.com](http://www.tvmlifescience.com)

#### **Media Contact:**

Dr. Hubert Birner, Managing Partner, [birner@tvm-capital.com](mailto:birner@tvm-capital.com)

Monika Schlesinger, Marketing & Communications, [schlesinger@tvm-capital.com](mailto:schlesinger@tvm-capital.com)

+49 89 998 992 0

### **About DPE**

DPE Deutsche Private Equity GmbH (DPE) is an independent German private equity investment company investing in small and medium-sized enterprises in Germany, Austria and Switzerland. DPE was founded in Munich in 2007 and has since successfully launched three funds, managing total assets of €1.2bn. Since 2007, DPE has invested in 19 companies both as majority and minority shareholder and pursued 47 add-on investments. As an active partner, DPE helps companies grow by providing them with the growth capital, experience, trust, respect and extensive support they need.

More information: [www.dpe.de/en](http://www.dpe.de/en)

### **Media Contact:**

Guido Prehn, Partner, [guido@dpe.de](mailto:guido@dpe.de)

+49 89 2000 38 190

### **About Careventures**

Careventures, based in Luxembourg, is a private equity fund that is a partner of choice for top healthcare companies and entrepreneurs leveraging its hand-on sector knowledge and swift access to capital. Careventures is focusing on healthcare services in Europe.

More information: [www.careventures.eu](http://www.careventures.eu)

### **Media Contact:**

Eric Souetre, Managing Partner, [eric.souetre@careventures.eu](mailto:eric.souetre@careventures.eu)

### **About CIC CAPITAL**

CIC Capital, the international private equity arm of CM-CIC Investissement (the equity financing arm of the Crédit Mutuel CM11 Group) meets the needs of businesses in all areas of equity financing. The success of our approach stems from our strong focus on people, our professionalism, our close ties with the management team and the long-term support we provide to portfolio companies. CM-CIC Investissement invests its own capital (€2.4 billion) in around 410 portfolio companies. CM-CIC Investissement has expanded its international activities under the CIC Capital brand from its original base in Canada (Montreal) into the USA (New York and Boston), Germany (Frankfurt), the UK (London) and Switzerland (Geneva and Zurich).

More information: [www.cmcic-investissement.com](http://www.cmcic-investissement.com)

### **Media Contact:**

Véronique Richez-Lerouge, [v.richez-lerouge@reso-media.com](mailto:v.richez-lerouge@reso-media.com)

+33 6 14 63 90 00